VERA
Vera Therapeutics, Inc. (VERA) Management Analysis (2026)
Overall Score
Leadership Execution
Management is operating with a very strong liquidity position, with a current ratio of 10.9x and cash per share of 6.95.
Execution remains challenged by negative profitability and cash generation, with ROE at -84.1% and free cash flow per share at -4.72.
Capital Allocation
The balance sheet remains conservative, with debt-to-equity at 0.18x and net debt to EBITDA near zero.
Capital allocation flexibility is supported by a cash ratio of 1.01x and working capital of 479.2M, but there is no evidence of durable earnings power yet.
Governance Incentives
No fresh news indicates a governance change or incentive reset this month.
The company still appears to be in a turnaround phase, so management credibility will depend on translating liquidity into sustained operating improvement.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

